[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 452
Citations 0
Comment & Response
December 17, 2014

Assessment of Outcomes of Hepatitis C Treatment—Reply

Author Affiliations
  • 1Department of Critical Care Medicine, National Institutes of Health, Bethesda, Maryland
  • 2Institute of Human Virology, University of Maryland School of Medicine, Baltimore
JAMA. 2014;312(23):2571. doi:10.1001/jama.2014.14905

In Reply Dr Chavez-Tapia and colleagues raise an important clinical question. Is SVR the appropriate clinical end point with new treatments for HCV or should clinical outcomes be assessed? Clinical outcomes of HCV include progression of liver fibrosis, decompensated liver disease, occurrence of hepatocellular carcinoma, and mortality, all of which take years to develop. In the interferon era of HCV therapeutics, occurrence of SVR was correlated with improved liver-related and overall outcomes, including hepatocellular carcinoma.1,2 Long-term follow-up studies of patients who achieve SVR need to be performed to evaluate whether interferon-free directly acting antiviral therapy reduces these outcomes. Our systematic review of the literature on advances in treatment regimens used to treat HCV cannot address this issue. However, we agree that measuring and defining the effect of treatment with directly acting antivirals for HCV on mortality is the next step and would help determine the value of treatment for various populations of patients (eg, those with various stages of liver disease, patients coinfected with human immunodeficiency virus, children). In addition, further delineation of the effect of therapy on the transmission of HCV is necessary from a public health perspective to understand and define the benefit of SVR on curtailing disease spread.

First Page Preview View Large
First page PDF preview
First page PDF preview